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Mucolipidosis II and III alpha/beta (ML II/III alpha/beta) are rare autosomal recessive lysosomal storage diseases
that are caused by a deﬁciency of UDP-GlcNAc:lysosomal enzyme N-acetylglucosamine-1-phosphotransferase,
the enzyme responsible for the synthesis of the mannose 6-phosphate targeting signal on lysosomal hydrolases.
A Brazilian patient suspected of having a verymildML III was investigated usingwhole next-generation sequenc-
ing (NGS). Twomutations in theGNPTAB genewere detected and conﬁrmed to be in trans status byparental anal-
ysis: c.1208TNC (p.Ile403Thr), previously reported as being pathogenic, and the novel mutation c.1723GNA
(p.Gly575Arg). This study demonstrates the effectiveness of using whole NGS for the molecular diagnosis of
very mild ML III alpha/beta patients.
© 2014 The Authors. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
(http://creativecommons.org/licenses/by-nc-nd/3.0/).
1. Introduction
In recent years, the use of massive parallel sequencing, or next-
generation sequencing (NGS), is revolutionizing genetic investigation
as well as clinical practice, mostly when dealing with rare diseases. It
is particularly useful when the same phenotype can be caused bymuta-
tions in different genes. As cost of sequencing is progressively coming
down, it is expected that in the near future comprehensive molecular
diagnosis will become a standard of care. NGS can be used in several
ways: as a panel targeting selected genes, as a test where the whole
exome (i.e., the ~2% coding regions of the genome) is captured and se-
quenced, or as an exam where the whole genome, with its coding and
non-coding regions, is sequenced. Even though sequencing a limited
number of genes is apparentlymore rationale than all genes, developing
several panels can be expensive and burdensome. Additionally, having a
single test (as whole exome or genome sequencing) for thousands of
different genetic disorders is practical and gives opportunities for new
discoveries.
Mucolipidosis II and III (ML II and III) are autosomal recessive lyso-
somal disorders (LSD) in which the essential mannose 6-phosphate
(Man-6-P) recognition marker system is deﬁcient. ML II and III are
caused by mutations in the GNPTAB or GNPTG genes, which encode the
subunits α and β (GNPTAB) or γ (GNPTG) of the N-acetylglucosamine-
1-phosphotransferase (phosphotransferase, EC 2.7.8.17). Phosphotrans-
ferase is a hexameric enzyme (2 α, 2 β, and 2 γ subunits) that mediates
the ﬁrst step of the synthesis of Man-6-P, but there are other genes in-
volved in this pathway, such as the NAGPA gene which encodes
“uncovering enzyme” (EC 3.1.4.45), (reviewed in [1]) and the MBTPS
gene that encodes the S1P enzyme. S1P or “site-1 protease” (EC
3.4.21.112) acts post-translationally to cleave the inactive α/β precursor
to generate the α and β subunits of mature phosphotransferase [2]. At
least theoretically, allelic mutations in the NAGPA orMBTPS genes could
cause ML II/III, even though they have never been reported.
ML is classiﬁed as II or III according to the clinical manifestations. Al-
though there is a phenotypic spectrum, ML II (MIM# 252500) is more
severe, clinically evident at birth, and usually fatal during childhood.
ML III (MIM# 252600 and 252605) has a later onset of symptoms and
slower progression. Clinically, skeletal alterations similar to dysostosis
multiplex, claw hands, failure to thrive, and coarse facial features are
observed. Milder cases may have a normal or near normal survival and
absence of cognitive involvement, but still present bone involvement
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and claw hands. Patients with ML II and most patients with ML III have
been found to be homozygous or compound heterozygous for mutations
inGNPTAB and, consequently, showalterations in subunits alpha and beta
(being called ML II or III alpha/beta patients). In addition, a second group
of ML III patients is homozygous or compound heterozygous for muta-
tions in GNPTG, present abnormal gamma subunit (thus being ML III
gamma patients) (reviewed in [3]). As the catalytic domain of phospho-
transferase is located in the α/β region, patients with ML III gamma are
believed to present the milder phenotypes. However, very few patients
are described with ML III gamma, which prevent us from making any
kind of generalization.
Schrader et al. [4] were the ﬁrst to demonstrate the effectiveness of
molecular diagnosis forML III usingNGS. Theywere able to show a 6-bp
deletion in the GNPTG gene in a family with retinitis pigmentosa and
skeletal abnormalities, patients who were not previously known to
have ML III. In turn, using targeted NGS, Yang et al. [5] identiﬁed two
homozygous nonsense mutations in the GNPTAB gene in two Chinese
families, patients who had previously been diagnosed through bio-
chemical assays as having ML II.
In this work, we evaluated the reliability and feasibility of molecular
diagnosis by whole exome sequencing for ML II/III.
2. Materials and methods
2.1. Cation-independent Man-6-P receptor (CI-MPR)
afﬁnity chromatography
25 μL of the patient's plasma or 200 μL plasma from 2 healthy
individuals was diluted in 50mM imidazole, 150mMNaCl, 0.05% Triton
X-100, pH = 6.5 (Buffer A) in a total volume of 1 mL and loaded on a
CI-MPR afﬁnity column [6]. The column was washed with 7 mL buffer
A, 10 mL buffer A containing 5 mM glucose 6-phosphate and eluted
with 5 mL buffer A containing 10 mMMan-6-P. The lysosomal enzyme
activitiesweremeasured in the plasma and the different fractions as de-
scribed [6]. All enzymatic reactions were performed in 50 mM citrate
buffer containing 0.5% Triton X-100, pH = 4.6.
2.2. Whole next-generation sequencing
Peripheral blood was extracted using Easy DNA kit (Invitrogen).
Whole genome sequencing was performed with Nextera Exome
Capture System, followed by NGS with Illumina HiSeq 2500 (Mendelics
Genomic Analysis). The study was approved by the Hospital de Clínicas
de Porto Alegre (HCPA) Research Ethics Committee.
3. Results
3.1. Case report
The ﬁrst child born to a non-consanguineous couple, this male
patient had normal development (e.g., walked at 10 months). At the
age of 4, claudicationwasﬁrst noted. Therewas nohistory of respiratory
infections or other signiﬁcant comorbidity. Since the age of 8, his weight
had been pN95, and his height, between p10 and 25 for his age. At the
age of 11, after being followed by an orthopedics service, he was re-
ferred to ourmedical genetics service for suspectedmultiple epiphyseal
dysplasia. His skeletal radiographs, however, were suggestive of a
lysosomal disorder (e.g., dysostosis multiplex was present) and showed
the following: a decrease in intervertebral spaces especially in the
thoracolumbar transition, a decrease in the T10 and T11 vertebrae,
oval-shaped L1/L2 vertebrae, ﬂattening of the head of the humerus
with an increase in the humerus-acromion distance, as well as bilateral
alterations in the femoral head suggestive of Legg–Calvé–Perthes
disease. His echocardiogram, complete ophthalmologic exam, and ab-
dominal echography were normal, as well as serum levels of calcium
(8.9 mg/dL; NRV = 8.9–10.7) and alkaline phosphatase (290 U/L;
NRV= 98–317). On physical exam, he presented normal head circum-
ference, atypical facies, varus knees, restricted range of motion of the
shoulders, wrists, and knees and absence of corneal clouding, claw
hands, and hepatosplenomegaly (Fig. 1). At the age of 14, his height
was 149 cm(pb 5) and at 18, 152 cm(p b 5). He attended regular school
and did not exhibit cognitive delay.
3.2. Biochemical analysis
Based on the clinical ﬁndings, the initial diagnosis raised was
mucopolysaccharidosis type IV A or Morquio A syndrome (MPS IV-A,
MIM# 253000), which was ruled out due to the normal activity of N-
acetylgalactosamine-6-sulfatase (EC 3.1.6.4) in leukocytes (Table 1).
As the patient exhibited dysostosis multiplex by X-ray, a biochemical
investigation for lysosomal storage disorders was requested, which
was suggestive ofML II/III (presence of an increased activity of lysosom-
al hydrolases in plasma and normal activity in leukocytes). Since there
were no ﬁbroblasts available for biochemical analysis, the presence of
Man-6-P-containing lysosomal acid hydrolases in the plasmawas inves-
tigated using CI-MPR afﬁnity chromatography. As shown in Table 2, this
analysis showed a striking decrease in phosphorylated acid hydrolases
in the patient's plasma compared to normal, consistentwith the diagno-
sis of ML II/III.
Although the investigation performed in this patient is considered
enough for conﬁrming ML II/III, due to the very mild clinical picture,
especially the absence of claw hands – which is an unexpected ﬁnding
even for ML III gamma – it was decided that whole NGS would be per-
formed, also aiming to exclude the presence of pathogenic mutation in
other genes involved in M6P biosynthesis (such as NAGPA andMBTPS).
3.3. Whole next-generation sequencing
Whole NGS generated 64,363,166 sequences, each target base
was read on average 92× and 94% of the target bases were read at
least 10×. Two heterozygous variants in GNPTAB were identiﬁed:
c.1208TNC (p.Ile403Thr), previously reported as deleterious [7], and
the novel variant c.1723GNA (p.Gly575Arg), which was not present in
more than 8000 normal controls (Exome Server Variant and 1000 Ge-
nomes), including 1000 Brazilians (processed as controls at theNGS lab-
oratory). No pathogenic variants were found in the GNPTG, NAGPA, and
MBTPS genes. This result was conﬁrmed by Sanger sequencing, and a
segregation study demonstrated that the father was a carrier of the
variant p.Ile403Thr, and the mother, of the transversion p.Gly575Arg.
Polyphen-2 predicted p.Gly575Arg as probably damaging (score of
0.974). Sift v.1.1.3 prediction indicated the variant p.Gly575Arg as toler-
ated/neutral. TheMutPred software interpreted the pathogenicity as an
actionable hypothesis, with a probability score of deleterious mutation
of 0.382, supposedly causing the following: gain of solvent accessibility
(p= 0.0171), gain of helix (p= 0.0425), gain of relative solvent acces-
sibility (p= 0.0479), loss of loop (p= 0.0512), and loss of methylation
at K573 (p = 0.0536).
4. Discussion
The aim of this work was to evaluate themolecular diagnosis of very
mild ML III using whole NGS, and our results demonstrate the utility of
this new technology.
The conﬁrmation of the clinical diagnosis of ML II/III faces several
challenges in regard to the performance of biochemical assays, since
these assays are not widely available (nor easily done) and depend on
the performance of ﬁbroblast biopsy. The phosphotransferase assay,
for instance, requires a radioactive substrate, is difﬁcult to implement,
and few groups in the world perform this assay.
Currently, biochemical diagnosis of ML II/III is usually performed in-
directly, through the measurement of lysosomal hydrolases both in
plasma (their activity should be high) and in ﬁbroblasts (their activity
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Fig. 1.Male patient with mucolipidosis type III, aged 14 years old, presenting a milder phenotype. A — Absence of hand joint contractures. B— Joint contractures in shoulders, hindering
arm elevation above the head; atypical facies. C —Whole body posterior image. The obesity is evident.
Table 1
Biochemical characterization of patient.
Biochemical investigation Sample Patient Reference Values
α-L-Iduronidase (EC 3.2.1.76) Plasma 119 6.8–13.7
β-Glucuronidase (EC 3.2.1.31) Plasma 906 30–300
α-N-acetylglucosaminidase (EC 3.2.1.50) Plasma 875 34–162
α-Mannosidase (EC 3.2.1.24) Plasma 2026 17–56
β-Hexosaminidases A (EC 3.2.1.30) Plasma 11,747 550–1675
β-Hexosaminidases B (EC 3.2.1.30) Plasma 27,535 265–1219
β-Hexosaminidases, total (EC 3.2.1.30) Plasma 39,282 1000–2857
Chitotriosidase (EC 3.2.1.14) Plasma 98 8.8–132
Iduronate 2-sulfatase (EC 3.1.6.12) Plasma 1716 122–463
β-Galactosidase (EC 3.2.1.23) Leukocyte 162 78–280
α-L-Iduronidase (EC 3.2.1.76) Leukocyte 72 32–56
Arylsulfatase B (EC 3.1.6.12) Leukocyte – 72–176
β-Glucosidase (EC 3.2.1.21) Leukocyte 19 10–45
α-N-acetylglucosaminidase (EC 3.2.1.50) Leukocyte 64 68–352
Iduronate 2-sulfatase (EC 3.1.6.12) Leukocyte 95 31–110
β-Glucuronidase (EC 3.2.1.31) Leukocyte 175 23–151
Sphingomyelinase (EC 3.1.4.12) Leukocyte 1.9 0.74–4.9
Total β-hexosaminidases (EC 3.2.1.30) Leukocyte 7384 552–16,662
β-Hexosaminidase A Leukocyte 53 150–390
N-acetylgalactosamine-6-sulfatase Leukocyte 29 14–81
Dosage of GAGs Urine 128 (79–256) b9 years: 44–106 mg/L
Thin-layer chromatography of GAGs Urine DS + HS + CS/HS Normal
Thin-layer chromatography of sialoligosaccharide Urine Normal Normal
GAGs: Glycosaminoglycans; –: not available; DS: dermatan sulfate; HS: heparan sulfate; CS: chondroitin sulfate.
36 F. Sperb-Ludwig et al. / Molecular Genetics and Metabolism Reports 2 (2015) 34–37
should be low).Whenﬁbroblasts are not available, other tests are needed
(such as the analysis of phosphorylated residues, which is also performed
on a research basis, or DNA analysis only). Moreover, as occurred in the
present case, the clinical picture can be so mild, sometimes limited to
bone disease, that even experienced physicians miss its diagnosis.
Regarding DNA analysis, there is no consensus about which gene
(GNPTAB or GNPTG) should be ﬁrst analyzed when facing a case with
clinical picture compatible with ML III. If the case is very mild, an initial
analysis of GNPTGmay be suggested, but, as reported herein, mutations
in GNPTABmight also cause verymild phenotypes. Among the available
technologies for DNA analysis, exome sequencing is one of themostmod-
ern tools available. It is important to point out that ML III presents locus
heterogeneity and that Sanger sequencing of whole coding GNPTG and
GNPTAB is made by ampliﬁcation and sequencing of the 11 and 21
exons of each gene, respectively, a situation that requires time and invest-
ment and can delay the diagnosis. In this regard, exome sequencing is a
reliable alternative for conﬁrmation of the diagnosis of ML III.
However, different sequencing platforms vary in their ability to
identify variants, even when sequencing the same genome. Besides
that, prediction of the pathogenicity of the novel missense variants
found is still a problem. For instance, the patient reported herein is a
compound heterozygote for two missense mutations in the GNPTAB
gene, p.Ile403Thr (a previously reported pathogenic mutation) and
p.Gly575Arg (a novel mutation which presents divergent results re-
garding its pathogenicity by bioinformatics analysis). Up to date, more
than 125 differentmutations of GNPTAB, encoding theα/β-subunit pre-
cursor of the phosphotransferase, have been described to causeML II or
III alpha/beta (HGMD, 2014). In general ML II alpha/beta patients have
nonsense, frameshift or splice-site mutations in GNPTAB, whereas ML
III alpha/beta patients carry missense mutations [8].
Franke, Braulke, & Storch [9] showed that for efﬁcient transport of
the α/β-subunit precursor protein from the ER to the Golgi apparatus,
a nonexchangeable dileucine (Leu 5-Leu 6) and the dibasic motif
(Arg1253-Ile1254-Arg1255) are required in its cytosolic N- and
C-terminal domains, respectively. After, the S1P-mediated cleavage
α/β-subunit precursor protein occurs in the Golgi apparatus, a pre-
requisite for the catalytic activity of phosphotransferase [10].
The mature human α-subunit is a type II membrane protein with an
N-terminal tail, a transmembrane region and a subsequent luminal do-
main, each one comprising 19, 22, and 886 amino acids respectively
[11,12]. The luminal domain contains 17 potential N-glycosylation
sites, and mutations associated to ML II and ML III are described in this
domain [12–14].
The missense mutation p.Gly575Arg changes a polar amino acid
(glycine, GGA) for an apolar (Arginine, AGA). It is located in the luminal
domain of the α-subunit, in a region with no homolog domains, but
next to an N-glycosylation site (N580). This residue and amino acid
(Gly575) is highly conserved in mammals, ﬁsh, amphibians, birds, but
not in zebraﬁsh and frogs, and might be a binding site for luminal ER
proteins required for ER exit of α/β-subunit precursor. Alternatively,
p.Gly575Arg can cause misfolding of the mutant protein and retention
in the ER [15]. Both alternatives could explain the pathogenicity of
p.Gly575Arg and the patient's mild phenotype. There is no other muta-
tion described in the 575 residue of phosphotransferase — the closest
one is p.Arg587Pro (c.1760GNC) which is also associated to ML III [16].
The following evidence also suggests p.Gly575Arg is pathogenic:
1) p.Ile403Thr is described in ML III patients [7,8,17] and is presumed
to be a mild mutation by expression studies [7]. The very mild pheno-
type of the patient could be explained by the fact he is compound het-
erozygous for two mild mutations (p.Ile403Thr and p.Gly575Arg);
2) no other mutations causing the phenotype were found in the
GNPTAB, GNPTG, NAGPA, and MBTPS genes; 3) both mutations found
are in trans and inherited; 4) p.Gly575Argwas not found in a high num-
ber of controls from the same population as the patient.
We agreewith Schrader et al. [4] and reinforce the idea that the costs
of NGS will gradually come down. As soon as this happens, this tech-
niquewill become themost direct approach for the diagnosis ofMende-
lian disorders that are phenotypically and genetically heterogeneous,
such as ML II/III. In the meantime, Sanger sequencing of GNPTAB and
GNPTG remains the ﬁrst strategy for DNA analysis of patients with ML
II/III.
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